Concepedia

Pavan Vaddady

PV

Statistics

Publications

8

Citations

385

H-Index

8

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Tennessee Health Science Center

St. Jude Children's Research Hospital

PRA Health Sciences

Pavan Vaddady is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2010–2023

8

Publications

8

Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux

Richard Lee, Julian G. Hurdle, Jiuyu Liu et al. · Nature Medicine · 2014 · 192 citations · Full text

, , +10

Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents

Jianjun Chen, Zhao Wang, Chien-Ming Li et al. · Journal of Medicinal Chemistry · 2010 · 120 citations

Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection

AW Krug, Pavan Vaddady, RA Railkar et al. · Clinical and Translational Science · 2017 · 16 citations · Full text

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy

Hwa-ping Feng, Zifang Guo, Luzelena Caro et al. · Clinical and Translational Science · 2018 · 14 citations · Full text

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma

Conrad Jacobs, Bernardo L. Rapoport, Graham Cohen et al. · Cancer Research · 2021 · 12 citations

, , +18

1–5 of 8